A multi-country, multicenter, single-arm, open-label study to document the safety, tolerability and effect of ALIROCUMAB on atherogenic lipoproteins in high cardio-vascular risk patients with severe hypercholesterolemia not adequately controlled with conventional lipid-modifying therapies